Board member of Immunovia purchases shares in the company
LUND, SWEDEN - Immunovia AB (publ) (“Immunovia”) announces today that board member Martin Møller purchases 1,056 shares in Immunovia, an investment of a total of SEK 141,295. This is Martin Møller's total holding after the purchase. For more information, please contact:Patrik Dahlen, CEO ImmunoviaEmail: patrik.dahlen@immunovia.comTel: +46 73 376 76 64 About ImmunoviaImmunovia AB is a diagnostic company that is developing and commercializing highly accurate blood tests for the early detection of cancer and autoimmune diseases based on Immunovia’s proprietary test platform